Demand Driven

A sudden change in the brain, delirium is an acute medical emergency affecting an estimated 70% of patients in critical care and 30% hospital-wide. Characterized by its sudden onset, agitation, and disorientation, delirium can be reversed if properly diagnosed and managed (unlike dementia which is progressive). While standard of care for decades has relied on antipsychotics and restraints to sedate and immobilize, research documents their devastating short and long-term implications. Multi-component non-pharmacological delirium reduction strategies do work – and MindfulGarden is an important bedside tool of care that will integrate effectively into all existing protocols with the v.1 product combining soundscapes, visuals, breathwork, and brain games in a ‘digital crashcart’ for delirium management..

Clinically Validated

MindfulGarden is the first clinically validated biofeedback platform for managing the agitated behaviours associated with hospital acquired delirium. Results of our foundational clinical study (NCT04652622) were published in NATURE npj/Digital Medicine in October 2023 highlighting a  25.7% reduction in use of PRN (as needed) antipsychotic drugs and a rapid de-escalation of agitation as measured by Richmond Agitation Sedation Scale (RASS) scores. The platform is independent of hospital IT, does not collect any personal health information, trains in minutes, and is easily deployed. MindfulGarden was approved by Health Canada as a Class 1 device (MDEL Lic.26563) in April 2024 and has completed its US FDA pre-submission. MindfulGarden V.1 has contracts with two Canadian hospital authorities for evaluation programs through 2025, with expansion to Hong Kong in 2025/26.

Patient-Powered

Harnessing biometrics to influence bio-state: MindfulGarden’s patent-pending affective biofeedback platform is built on a game engine, responding to patient generated distress signals and translating the data to gently moving nature-based visualizations and sounds onscreen that level up or down as the patient calms. The goal is to distract, engage, and de-escalate adverse behaviours before the administration of drugs are considered, allowing the patient to return to homeostasis. MindfulGarden is ultimately creating the framework in which biofeedback influences the biostate of the user. R&D is underway on V.2 MindfulGarden, exploring the harnessing of vital signs to ‘drive’ interactivity onscreen, measure patient’s physiological response to exposure to MindfulGarden,  and facilitate a patient’s ability to self-calm. As one nurse described MindfulGarden –  “it’s the video game played by the body that the body doesn’t even know it’s playing.”